Micro- and nanotechnological delivery platforms for treatment of dysbiosis-related inflammatory bowel disease-Reference-Cited by-同舟云学术

Micro- and nanotechnological delivery platforms for treatment of dysbiosis-related inflammatory bowel disease

Published:2021-08 Issue:20 Volume:16 Page:1741-1745
ISSN:1743-5889
Container-title:Nanomedicine
language:en
Short-container-title:Nanomedicine

Author:

Long Dingpei¹^ORCID,Merlin Didier¹²

Affiliation:

1. Institute for Biomedical Sciences, Center for Inflammation, Immunity & Infection, Digestive Disease Research Group, Georgia State University, Atlanta, GA 30302, USA

2. Atlanta Veterans Affairs Medical Center, Decatur, GA 30033, USA

Funder

U.S. Department of Veterans Affairs

Research Fellowship Award from the Crohn's and Colitis Foundation of America

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

Future Medicine Ltd

Subject

Development,General Materials Science,Biomedical Engineering,Medicine (miscellaneous),Bioengineering

Link

https://www.futuremedicine.com/doi/pdf/10.2217/nnm-2021-0167

Reference31 articles.

1. Inflammatory bowel disease

2. Future biologic targets for IBD: potentials and pitfalls

3. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?

4. The Gut Microbiota in Immune-Mediated Inflammatory Diseases

5. Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of Inflammatory Bowel Diseases and Therapeutic Approaches

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent progress on engineered micro/nanomaterials mediated modulation of gut microbiota for treating inflammatory bowel disease;Journal of Controlled Release;2024-06

2. Crohn’s Disease and Ulcerative Colitis: From Pathophysiology to Novel Therapeutic Approaches;Biomedicines;2024-03-19

3. Oral administration of M13-loaded nanoliposomes is safe and effective to treat colitis-associated cancer in mice;Expert Opinion on Drug Delivery;2023-07-02

4. Gut microbial metabolome in inflammatory bowel disease: From association to therapeutic perspectives;Computational and Structural Biotechnology Journal;2022